MPN Workshop of the Carolinas 2025 | Practical advice for community physicians managing patients with anemia and myelofibrosis

So I think the two key considerations are not just focusing on the anemia, but the rest of the patient as well. You know, what are their symptoms and splenomegaly doing? And you have to still address those. And you can’t use suboptimal levels of JAK inhibitor because you won’t be able to address those things while trying to preserve red cell production. And I think the other piece of the advice is really switching through medications, right? So as I mentioned earlier, anemia is multifactorial for patients with myelofibrosis, and any one given agent may not work. So if you try an ESA or luspatercept, and the anemia is not getting better, perhaps switching to something else, or you start out with, say, an ACVR2 inhibitor, like momelotinib, and it’s not working, switching to something else or adding something else on top. So try a new agent, give it some time, a few months. And if it’s not working and you’ve maxed out the dose level for that drug, switch your strategy. Because there are several options that are commercially available now, and they all work differently. And since anemia, again, is multifactorial, you may have to do a little bit of scientific guessing and educate as you work through all the different aspects of a patient’s anemia to get the eventual response you need.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.